FORM	4

(Print or Type Perponses)

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person – NOWOTNIK DAVID P	2. Issuer Name and ACCESS PHARM					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) ACCESS PHARMACEUTICALS IN STEMMONS FRWY STE 176	G 0 (00	3. Date of Earliest Transaction (Month/Day/Year) 05/21/2008						X Officer (give title below) Other (specify below) Sr Vice President R&D			
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year) DALLAS, TX 752072107							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	r) Execution Date, if Code (Arrows any (Instr. 8)		(A) or Disposed of (D)			Transaction(s)	6. Ownership Form:	Beneficial		
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	1	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
Security	Conversion	3. Transaction Date (Month/Day/Year)	Execution Date, if	Code	tion)	5. Number		6. Date Exercisa Expiration Date (Month/Day/Yea	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Exercisable	Expiration Date		Amount or Number of Shares				
Stock option (right to buy)	\$ 3	05/21/2008		А		12,500		05/21/2009	05/21/2018	Common stock	12,500	\$ 3	172,500	D	
Stock option (right to buy)	\$ 3	05/21/2008		А		37,500		06/21/2009 <mark>(1)</mark>	05/21/2018	Common stock	37,500	\$ 3	210,000	D	

Reporting Owners

Bernardian Orman Nama (Addama	Relationships							
Reporting Owner Name / Address		10% Owner	Officer	Other				
NOWOTNIK DAVID P ACCESS PHARMACEUTICALS INC 2600 STEMMONS FRWY STE 176 DALLAS, TX 752072107			Sr Vice President R&D					

Signatures

David P. Nowotnik (by Stephen B. Thompson) 05/22/2008 **Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) After twelve months from the Grant Date option vest 2.0833% monthly, all options vested 48 months from the Grant Date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.